Delayed-onset primary cytomegalovirus disease after liver transplantation

Liver Transplantation

Volumn 13, Issue 12, 2007, Pages 1703-1709

  Arthurs, Supha K ^a   Eid, Albert J ^a   Pedersen, Rachel A ^a   Dierkhising, Ross A ^a   Kremers, Walter K ^a   Patel, Robin ^a   Razonable, Raymund R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOSCARNET; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; AGE; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL INFECTION; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; ORGAN DONOR; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; SURGICAL INFECTION; SURGICAL MORTALITY; SURVIVAL RATE; THERAPY RESISTANCE; TREATMENT DURATION; VIRUS HEPATITIS;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; TIME FACTORS;

EID: 37549071844     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21280     Document Type: Article

References (33)

1. Paya C, Razonable RR. Cytomegalovirus infection after solid organ transplantation. In: Bowden R, Ljungman P, Paya C, eds. Transplant Infections. Vol 1. Philadelphia, PA: Lippincott, Williams and Wilkins; 2003:298-325.
2. de Otero J, Gavalda J, Murio E, Vargas V, Calico I, Llopart L, et al. Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation. Clin Infect Dis 1998;26:865-870.
3. Burak KW, Kremers WK, Batts KP, Wiesner RH, Rosen CB, Razonable RR, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002;8: 362-369.
4. Rosen HR, Chou S, Corless CL, Gretch DR, Flora KD, Boudousquie A, et al. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 1997;64:721-726.
5. Falagas ME, Snydman DR, Griffith J, Ruthazer R, Werner BG. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. Ann Intern Med 1997;126:275-279.
6. van den Berg AP, Klompmaker IJ, Haagsma EB, Peeters PM, Meerman L, Verwer R, et al. Evidence for an increased rate of bacterial infections in liver transplant patients with cytomegalovirus infection. Clin Transplant 1996;10:224-231.
7. Slifkin M, Ruthazer R, Freeman R, Bloom J, Fitzmaurice S, Fairchild R, et al. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation. Liver Transpl 2005;11:1597-1602.
8. Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, et al. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? Transplant Proc 2005;37: 3182-3186.
9. Limaye AP, Bakthavatsalam R, Kiro HW, Kuhr CS, Halldorson JB, Healey PJ, et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004;78:1390-1396.
10. Limaye AP, Bakthavatsalam R, Kim HW, Randolph SE, Halldorson JB, Healey PJ, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006;81:1645-1652.
11. Freeman RB, Paya C, Pescovitz MD, Humar A, Dominguez E, Washburn K, et al. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation 2004;78:1765-1773.
12. Razonable RR, Rivero A, Rodriguez A, Wilson J, Daniels J, Jenkins G, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184:1461-1464.
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
14. Cytomegalovirus. Am J Transplant 2004;4(suppl 10):51-58.
15. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002;34:1094-1097.
16. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004;4:611-620.
17. Humar A, Paya C, Pescovitz MD, Dominguez E, Washburn K, Blumberg E, et al. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R-solid organ transplant recipients. Am J Transplant 2004; 4:644-649.
18. Razonable RR. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm 2005;62(suppl 1):S7-S13.
19. Kijpittayarit S, Deziel P, Eid AJ, Razonable RR. Primary cytomegalovirus disease after five years of antiviral prophylaxis. Transplantation 2006;81:137-138.
20. Boivin G, Gilbert C, Gaudreau A, Greenfield I, Sudlow R, Roberts NA. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J Infect Dis 2001;184:1598-1602.
21. Jain PT, Gewirtz DA. Estradiol enhances gene delivery to human breast tumor cells. J Mol Med 1998;76:709-714.
22. Jain PT, Seth P, Gewirtz DA. Estradiol enhances liposome-mediated uptake, preferential nuclear accumulation and functional expression of exogenous genes in MDA-MB231 breast tumor cells. Biochim Biophys Acta 1999;1451:224-232.
23. Hjelmesacth J, Jenssen T, Hagen M, Egeland T, Hartmann A. Determinants of insulin secretion after renal transplantation. Metabolism 2003;52:573-578.
24. Hjelmesaeth J, Sagedal S, Hartmann A, Rollag H, Egeland T, Hagen M, et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004;47:1550-1556.
25. Hartmann A, Sagedal S, Hjelmesaeth J. The natural course of cytomegalovirus infection and disease in renal transplant recipients. Transplantation 2006;82(suppl): S15-S17.
26. Hafiz MM, Poggioli R, Caulfield A, Messinger S, Geiger MC, Baidal DA, et al. Cytomegalovirus prevalence and transmission after islet allograft transplant in patients with type 1 diabetes mellitus. Am J Transplant 2004;4:1697-1702.
27. Lo A, Stratta RJ, Egidi MF, Shokouh-Amiri MH, Grewal HP, Kisilisik AT, et al. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis. Transpl Infect Dis 2001;3:8-15.
28. Kaufman DB, Iii GW, Bruce DS, Johnson CP, Gaber AO, Sutherland DE, et al. Prospective, randomized, multi-center trial of antibody induction therapy in simultaneous pancreas-kidney transplantation. Am J Transplant 2003; 3:855-864.
29. Kaufman DB, Leventhal JR, Gallon LG, Parker MA, Koffron AJ, Fryer JP, et al. Risk factors and impact of cytomegalovirus disease in simultaneous pancreas-kidney transplantation. Transplantation 2001;72:1940-1945.
30. Hellinger WC, Bonatti H, Machicao VI, Yao JD, Brumble LM, Alvarez S, et al. Effect of antiviral chemoprophylaxis on adverse clinical outcomes associated with cytomegalovirus after liver transplantation. Mayo Clin Proc 2006;81: 1029-1033.
31. Hodson EM, Jones CA, Webster AC, Strippoli GF, Barclay PG, Kable K, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005;365:2105-2115.
32. Scientific Registry of Transplant Recipients 2005 annual report summary table, Table 1.13. Available at: http://www.ustransplant.org. Accessed September 5, 2006.
33. Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004;4:928-936.